Next Article in Journal / Special Issue
Comparative Genomics among Closely Related Streptomyces Strains Revealed Specialized Metabolite Biosynthetic Gene Cluster Diversity
Previous Article in Journal
Relationship between Maternal and First Year of Life Dispensations of Antibiotics and Antiasthmatics
Previous Article in Special Issue
Natural Products from Actinobacteria Associated with Fungus-Growing Termites
Article Menu

Export Article

Open AccessReview
Antibiotics 2018, 7(4), 85; https://doi.org/10.3390/antibiotics7040085

Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?

Fundación MEDINA, Avda Conocimiento 34, 18016 Granada, Spain
Received: 6 August 2018 / Revised: 20 September 2018 / Accepted: 21 September 2018 / Published: 25 September 2018
(This article belongs to the Special Issue Actinomycetes: The Antibiotics Producers)
Full-Text   |   PDF [2258 KB, uploaded 25 September 2018]   |  

Abstract

The current spread of multi-drug resistance in a number of key pathogens and the lack of therapeutic solutions in development to address most of the emerging infections in the clinic that are difficult to treat have become major concerns. Microbial natural products represent one of the most important sources for the discovery of potential new antibiotics and actinomycetes have been one of the most relevant groups that are prolific producers of these bioactive compounds. Advances in genome sequencing and bioinformatic tools have collected a wealth of knowledge on the biosynthesis of these molecules. This has revealed the broad untapped biosynthetic diversity of actinomycetes, with large genomes and the capacity to produce more molecules than previously estimated, opening new opportunities to identify the novel classes of compounds that are awaiting to be discovered. Comparative genomics, metabolomics and proteomics and the development of new analysis and genetic engineering tools provide access to the integration of new knowledge and better understanding of the physiology of actinomycetes and their tight regulation of the production of natural products antibiotics. This new paradigm is fostering the development of new genomic-driven and culture-based strategies, which aims to deliver new chemical classes of antibiotics to be developed to the clinic and replenish the exhausted pipeline of drugs for fighting the progression of infection diseases in the near future. View Full-Text
Keywords: actinomycetes; antibiotics; secondary metabolism; culture-based approaches; omics actinomycetes; antibiotics; secondary metabolism; culture-based approaches; omics
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Genilloud, O. Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm? Antibiotics 2018, 7, 85.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top